South Korea's pharmaceutical and biotech industry is witnessing a fascinating shift as Contract Development and Manufacturing Organizations (CDMOs) and biosimilar developers are experiencing robust growth, while traditional pharmaceutical companies lag. At the forefront of this transition is
In October 2023, Sanofi, a leading global pharmaceutical company, announced a major shift in its business strategy. This shift involved the separation of its consumer health division, a move set to be completed in 2024. Historically, Sanofi's consumer health division, which includes popular
Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing
October 2024 saw a surge in biotech investments, with notable contributions from companies across North America, Europe, and the Asia-Pacific regions. Major players like Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics secured substantial funding, reflecting the growing
Innovent Biologics Inc. (1801.HK), a significant player in the Chinese biopharmaceutical sector, recently faced harsh backlash from investors due to a misstep in its strategy. The company aimed to strengthen its executives' dedication to its international unit, Fortvita, by selling a stake to the
ApiJect Systems Corp., a public-benefit medical technology company, has recently secured an initial grant of $425,000 from the Bill & Melinda Gates Foundation. This significant funding aims to support the design and development of low-cost Prefilled ApiJect Injectors to make single-use prefilled
